Ioflupane I 123

CHEMBL3989517 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
427.3 g/mol
LogP
4.0
Phase
4

A radioactive imaging agent used in SPECT brain scans to help diagnose Parkinson's disease and related movement disorders. It attaches to dopamine transporters in the brain, allowing doctors to assess dopamine activity.

Masse moléculaire

427,3000 g/mol

LogP

4,00

TPSA

29,50 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COC(=O)[C@H]1[C@@H](c2ccc([123I])cc2)C[C@@H]2CC[C@H]1N2CCCF

InChI

InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4

Molecular Formula

C18H23FINO2

HBD / HBA

- / 4

Liaisons Rotatives

6

Atomes Lourds

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A radioactive imaging agent used in SPECT brain scans to help diagnose Parkinson's disease and related movement disorders. It attaches to dopamine transporters in the brain, allowing doctors to assess dopamine activity.

Yes, Ioflupane I 123 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989517. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3086674. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.